Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 0.70 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23320381 | 0.82 | NAMPT (1.00) | NAMPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL23432009 | 0.78 | NAMPT (0.77) | NAMPT | |
| SCHEMBL23320402 | 0.77 | NAMPT (0.81) | NAMPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL29802090 | 0.75 | CASP3 (0.70) | NAMPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL29802067 | 0.75 | CASP3 (0.70) | NAMPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL26932345 | 0.75 | CASP3 (0.70) | NAMPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL26932297 | 0.75 | CASP3 (0.70) | NAMPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL26932280 | 0.75 | CASP3 (0.73) | NAMPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL29802221 | 0.75 | CASP3 (0.73) | NAMPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL23320408 | 0.74 | NAMPT (0.84) | NAMPTNPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654608-A | Condensed ring compounds having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2021-04-13 | — | — | CN | claimed |
| CN-112654608-B | Fused ring compound having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2024-05-07 | — | — | CN | disclosed |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
| CN-112654608-A | Condensed ring compounds having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2021-04-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, ABAT | NAMPT 1/4885CASP3 1899/4885SENP8 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.